Maximum likelihood analysis of mammalian p53 indicates the presence of positively selected sites and higher tumorigenic mutations in purifying sites.

The tumor suppressor gene TP53 (p53) maintains genome stability. Mutation or loss of p53 is found in most cancers. Analysis of evolutionary constrains and p53 mutations reveal important sites for concomitant functional studies. In this study, phylogenetic analyses of the coding sequences of p53 from 26 mammals were carried out by applying a maximum likelihood method. The results display two branches under adaptive evolution in mammals. Moreover, each codon of p53 was analyzed by the PAML method for presence of positively selected sites. PAML identified several statistically significant amino acids that undergo positive selection. The data indicates that amino acids responsible for the core functions of p53 are highly conserved, while positively selected sites are predominantly located in the N- and C-terminus of p53. Further analysis of evolutionary pressure and mutations showed the occurrence of more frequent tumorigenic mutations in purifying sites of p53.

[1]  G. Glazko,et al.  P53 Gain-of-Function: Tumor Biology and Bioinformatics Come Together , 2005, Cell cycle.

[2]  R. Birgander,et al.  Is p53 polymorphism maintained by natural selection? , 1994, Human heredity.

[3]  T. Crook,et al.  TP53 mutations in familial breast cancer: Functional aspects , 2003, Human mutation.

[4]  S. Tornaletti,et al.  Complete and tissue-independent methylation of CpG sites in the p53 gene: implications for mutations in human cancers. , 1995, Oncogene.

[5]  R. Nielsen,et al.  Synonymous and nonsynonymous rate variation in nuclear genes of mammals , 1998, Journal of Molecular Evolution.

[6]  Thierry Soussi,et al.  The UMD‐p53 database: New mutations and analysis tools , 2003, Human mutation.

[7]  K. Harms,et al.  The C Terminus of p53 Family Proteins Is a Cell Fate Determinant , 2005, Molecular and Cellular Biology.

[8]  Z. Yang,et al.  Likelihood ratio tests for detecting positive selection and application to primate lysozyme evolution. , 1998, Molecular biology and evolution.

[9]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.

[10]  S. Tornaletti,et al.  UV light as a footprinting agent: modulation of UV-induced DNA damage by transcription factors bound at the promoters of three human genes. , 1995, Journal of molecular biology.

[11]  C. Arrowsmith.  Structure and function in the p53 family , 1999, Cell Death and Differentiation.

[12]  C. Ishioka,et al.  Locus-specific mutation databases: pitfalls and good practice based on the p53 experience , 2006, Nature Reviews Cancer.

[13]  Y. Miki,et al.  The cell death machinery governed by the p53 tumor suppressor in response to DNA damage , 2010 .

[14]  D. Lane,et al.  Cancer. p53, guardian of the genome. , 1992, Nature.

[15]  Yu-Zhen Li,et al.  p53 Initiates Apoptosis by Transcriptionally Targeting the Antiapoptotic Protein ARC , 2007, Molecular and Cellular Biology.

[16]  M. Tang,et al.  Cytosine methylation determines hot spots of DNA damage in the human P53 gene. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Ford.  Effects of natural selection on patterns of DNA sequence variation at the transferrin, somatolactin, and p53 genes within and among chinook salmon (Oncorhynchus tshawytscha) populations , 2000, Molecular ecology.

[18]  Vladimir A. Ivanisenko,et al.  Phylogenetic Analysis of the p53 and p63/p73 Gene Families , 2007, Silico Biol..

[19]  Ziheng Yang,et al.  Codon-substitution models to detect adaptive evolution that account for heterogeneous selective pressures among site classes. , 2002, Molecular biology and evolution.

[20]  C. Harris,et al.  Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. , 1996, Journal of the National Cancer Institute.

[21]  C. Fenoglio-Preiser,et al.  TP53 and gastric carcinoma: A review , 2003, Human mutation.

[22]  C. Harris,et al.  p53: 25 years after its discovery. , 2004, Trends in pharmacological sciences.

[23]  Toshihide Tsuda,et al.  The TP53 gene, tobacco exposure, and lung cancer , 2003, Human mutation.

[24]  B. Iacopetta.  TP53 mutation in colorectal cancer , 2003, Human mutation.

[25]  R. Nielsen,et al.  Codon-substitution models for detecting molecular adaptation at individual sites along specific lineages. , 2002, Molecular biology and evolution.

[26]  N. Kolchanov,et al.  [Phylogenetic analysis of the family of p53]. , 2006, Biofizika.

[27]  Ziheng Yang.  PAML 4: phylogenetic analysis by maximum likelihood. , 2007, Molecular biology and evolution.

[28]  N. Goldman,et al.  A codon-based model of nucleotide substitution for protein-coding DNA sequences. , 1994, Molecular biology and evolution.

[29]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[30]  S. Rodin,et al.  Origins and selection of p53 mutations in lung carcinogenesis. , 2005, Seminars in cancer biology.

[31]  Thierry Soussi,et al.  Significance of TP53 mutations in human cancer: A critical analysis of mutations at CpG dinucleotides , 2003, Human mutation.

[32]  S. Douc-Rasy,et al.  TP53 family members and human cancers , 2003, Human mutation.

[33]  Wojciech Makalowski,et al.  Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features , 1999, Oncogene.

[34]  Shinichi Aizawa,et al.  Heat shock induces transient p53-dependent cell cycle arrest at G1/S , 1997, Oncogene.

[35]  L. Wiesmüller,et al.  DNA double-strand break repair activities in mammary epithelial cells--influence of endogenous p53 variants. , 2009, Carcinogenesis.